title: Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death.
abstract: OBJECTIVE
  The aim of this study was to compare the efficacy and safety of induction therapy using the interleukin-2 receptor antagonist (IL-2RA) with antithymocyte globulin (ATG) under a tacrolimus-based immunosuppression regimen in kidney transplantation from donors after cardiac death.
  
  
  METHODS
  It was a single-centre, retrospective, cohort study design to evaluate the efficacy and safety of IL-2RA vs. ATG induction therapy in adult renal transplant recipients from donors after cardiac death. The primary end-point was the incidence of biopsy-proven acute rejection (BPAR) at 6 months, and the secondary end-point included the incidence of delayed graft function (DGF), the renal function, and the patient and graft survival at 6 months. The safety end-point was the incidence of infectious complications.
  
  
  RESULTS
  A total of 132 patients (n = 37 in the IL-2RA group and n = 95 in the ATG group) were enrolled from March 2013 to April 2014. The BPAR at 6 months was similar between the two groups (IL-2RA vs. the ATG group, 5.4% vs. 12.6%, respectively, p = 0.228). There were no differences in the DGF, renal function at 1 and 3 months, and the patient and graft survival at 6 months between the two groups, but the renal function at 6 months in the IL-2RA group was superior to that of the ATG group (p = 0.02). The IL-2RA group experienced less infection than the ATG group (p = 0.025).
  
  
  CONCLUSIONS
  The efficacy of IL2-RA and ATG induction under a tacrolimus-based immunosuppression regimen in low-risk DCD transplantation did not differ, but the safety of the IL2-RA induction was better than that of the ATG induction.
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang, China.|Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health, Zhejiang, China.|Kidney Disease Immunology Lab, The Third Grade Lab, State Administration of Traditional Chinese Medicine, Hangzhou Zhejiang, China.
authors.forename: W
authors.initials: W
authors.lastname: Peng
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang, China.|Kidney Disease Immunology Lab, The Third Grade Lab, State Administration of Traditional Chinese Medicine, Hangzhou Zhejiang, China.
authors.forename: G
authors.initials: G
authors.lastname: Liu
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang, China.
authors.forename: W
authors.initials: W
authors.lastname: Xie
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang, China.|Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health, Zhejiang, China.
authors.forename: H
authors.initials: H
authors.lastname: Huang
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang, China.|Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health, Zhejiang, China.|Kidney Disease Immunology Lab, The Third Grade Lab, State Administration of Traditional Chinese Medicine, Hangzhou Zhejiang, China.
authors.forename: J
authors.initials: J
authors.lastname: Wu
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang, China.|Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health, Zhejiang, China.|Kidney Disease Immunology Lab, The Third Grade Lab, State Administration of Traditional Chinese Medicine, Hangzhou Zhejiang, China.
authors.forename: Z
authors.initials: Z
authors.lastname: Shou
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang, China.|Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health, Zhejiang, China.|Kidney Disease Immunology Lab, The Third Grade Lab, State Administration of Traditional Chinese Medicine, Hangzhou Zhejiang, China.
authors.forename: J
authors.initials: J
authors.lastname: Chen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy* / Q000378:metabolism; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors*; D012189:Retrospective Studies; D016559:Tacrolimus; D014019:Tissue Donors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D016559:Tacrolimus